Primary Biliary Cholangitis

Epidemiology

Primary Biliary Cholangitis is an uncommon, chronic autoimmune cholestatic liver disease with a clear female predominance and typical onset in mid‑adult life.

Prevalence and incidence: reported prevalence varies by region and case ascertainment; incidence commonly estimated near 1–3 per 100,000 person‑years with prevalence increasing with age.
Sex distribution: historically female:male ratios near 9–10:1; contemporary series report narrowing ratios in some cohorts, though women remain the majority.
Age: highest prevalence in middle‑aged to older adults; pediatric onset is rare.
Genetics: familial aggregation and genetic susceptibility with HLA and multiple non‑HLA loci implicated.

Pathogenesis

PBC arises from loss of immune tolerance to biliary epithelial cell antigens, especially the E2 component of the pyruvate dehydrogenase complex, producing a T‑cell mediated chronic, non‑suppurative destructive cholangitis that targets small intrahepatic bile ducts.

Immune mechanism: autoreactive T lymphocytes and B cell autoantibodies contribute to selective destruction of small intrahepatic bile ducts.
Triggers: environmental exposures, infections, xenobiotics, and disturbances in cholangiocyte homeostasis (for example, impaired bicarbonate umbrella function) are implicated.
Histology: lymphocytic and often granulomatous portal inflammation with progressive ductopenia on biopsy.

Clinical Manifestations

Clinical presentation ranges from asymptomatic biochemical cholestasis to symptomatic cholestasis and advanced liver disease.

Asymptomatic: many patients are diagnosed incidentally by cholestatic liver tests.
Common symptoms: fatigue, pruritus, sicca symptoms including dry eyes and dry mouth, and right upper quadrant discomfort.
Progressive features: jaundice, steatorrhea, malabsorption of fat‑soluble vitamins, metabolic bone disease, portal hypertension, and cirrhosis in untreated or advanced disease.
Extrahepatic autoimmune disease: frequent coexisting autoimmunity such as thyroid disease, Sjögren syndrome, systemic sclerosis, and rheumatoid conditions.
Laboratory pattern: cholestatic enzyme profile with predominant alkaline phosphatase (ALP) and gamma‑glutamyl transferase (GGT) elevation; serum IgM often elevated.

Diagnosis

Diagnosis is usually established by a combination of cholestatic liver biochemistry, disease‑specific serology, and exclusion of alternative causes.

Core diagnostic elements

Biochemistry: persistent elevation of ALP consistent with cholestasis.
Serology: antimitochondrial antibody (AMA) is positive in approximately 90–95% of classic cases; PBC‑specific antinuclear antibodies such as anti‑gp210 and anti‑sp100 are helpful in AMA‑negative patients.
Imaging: abdominal ultrasound and MRCP are used to exclude extrahepatic biliary obstruction and large‑duct cholangiopathy; MRCP is indicated when large‑duct disease or cholangiopathy is suspected.
Liver biopsy: not required when cholestasis and characteristic serology are present; reserved for atypical serology, suspected overlap with autoimmune hepatitis, or uncertain staging.
Noninvasive staging: transient elastography and serum fibrosis scores are used to stage fibrosis and guide prognosis and transplant referral timing.

Special diagnostic considerations

AMA‑negative disease: test for PBC‑specific ANAs; consider biopsy when serology is inconclusive.
Overlap syndromes: diagnostic criteria require clinicopathologic correlation when autoimmune hepatitis features are present alongside PBC features.
Exclude secondary causes: evaluate for prolonged extrahepatic obstruction, medications, ischemic or infectious causes of ductal injury when presentation is atypical.

Treatment

Treatment goals are to slow disease progression, relieve symptoms, prevent complications, and evaluate for liver transplantation when appropriate.

First‑line therapy

Ursodeoxycholic acid (UDCA) at approximately 13–15 mg/kg/day lifelong unless intolerant; improves biochemical markers and long‑term outcomes in responders.

Second‑line and add‑on therapies

Obeticholic acid (OCA): approved as second‑line therapy for patients with incomplete UDCA response or UDCA intolerance.
Fibrates (bezafibrate, fenofibrate): evidence supports use for biochemical nonresponders and symptomatic control in some guidelines and practice; often used off‑label depending on region.
Investigational agents: PPAR agonists, antifibrotic agents, and targeted immunomodulators are under study for UDCA‑refractory disease.

Symptomatic and supportive care

Pruritus management: cholestyramine as first line for many patients; rifampin, naltrexone, or sertraline are alternatives for refractory pruritus.
Vitamin supplementation: monitor and replace fat‑soluble vitamins A, D, E, and K when deficient.
Bone health: screen for osteopenia/osteoporosis; ensure calcium and vitamin D adequacy and consider bisphosphonates when indicated.
Endoscopic or radiologic intervention: reserved for complications such as dominant strictures or cholangitis if large‑duct involvement occurs.
Liver transplantation: definitive treatment for end‑stage liver disease, refractory symptoms, or complications of portal hypertension; post‑transplant recurrence of PBC can occur.

Prognosis and Risk Stratification

Outcomes have improved with UDCA and modern risk stratification tools; early diagnosis and biochemical response predict better prognosis.

UDCA response: biochemical response to UDCA at 6–12 months is a validated predictor of transplant‑free survival.
Risk scores: continuous scores (for example, validated models used in adult hepatology practice) combine baseline and on‑treatment variables to estimate prognosis and guide management.
Risk factors for progression: advanced fibrosis at diagnosis, inadequate ALP reduction on therapy, elevated bilirubin, certain autoantibodies (for example anti‑gp210), and male sex in some cohorts.
Malignancy risk: small but increased risk of hepatocellular carcinoma in patients with cirrhosis; surveillance indicated when cirrhosis is present.

Pediatric Considerations

Primary Biliary Cholangitis is rare in children; most pediatric cholestatic disease has alternative causes. When PBC is considered, pediatric‑specific evaluation and management principles apply.

Incidence and presentation

Rarity: true pediatric PBC is exceptional, most reported cases occur in post‑pubertal adolescents.

Diagnostic approach for pediatric gastroenterologists

Prioritize common pediatric causes: exclude biliary atresia, genetic and metabolic cholestatic disorders, cystic fibrosis, autoimmune hepatitis, and primary sclerosing cholangitis before diagnosing PBC.
Age‑appropriate testing: interpret ALP and other labs with pediatric reference ranges; measure GGT, conjugated bilirubin, immunoglobulins, AMA, and PBC‑specific ANAs when indicated.
Imaging: ultrasound and MRCP to exclude extrahepatic obstruction; MRCP if cholangiopathy is suspected.
Biopsy: consider when serology is non‑diagnostic, overlap with autoimmune hepatitis is suspected, or staging is needed.

Management priorities

UDCA: dosing must be adjusted by weight; initiate therapy promptly when diagnosis is established and monitor biochemical response at 6–12 months.
Bone health: adolescence is a critical period for bone accrual; proactively address vitamin D, calcium, nutritional status, and consider early treatment for low bone density.
Overlap syndromes: consider combined immunosuppression plus UDCA when autoimmune hepatitis features are present; multidisciplinary discussion with adult hepatology may be helpful for complex cases.
Psychosocial support: address fatigue, pruritus, and the psychosocial impact of chronic disease in adolescents with multidisciplinary resources including mental health and social work.

Practical Follow Up and Clinic Guidance

Initiate UDCA at diagnosis and reassess biochemical response at 6–12 months to determine need for add‑on therapy.
Monitor fibrosis with noninvasive tools at baseline and periodically to detect progression and time referral for transplant evaluation.
Screen for associated autoimmune conditions and manage extrahepatic complications including fat‑soluble vitamin deficiencies and metabolic bone disease.
In AMA‑negative cholestasis test for PBC‑specific ANAs and consider liver biopsy when diagnosis remains uncertain.
Coordinate care with hepatology, endocrinology for bone health, nutrition, and mental health services, particularly for pediatric and adolescent patients.

Key Clinical Pearls

AMA positivity is highly specific and is present in most classic adult cases; AMA‑negative PBC exists and requires testing for PBC‑specific ANAs or biopsy for confirmation.
Response matters: biochemical response to UDCA is the single most practical early indicator of long‑term outcome and directs escalation of therapy.
Pediatric vigilance: because PBC is rare in children, maintain a broad differential for cholestasis and use age‑appropriate reference ranges and multidisciplinary input.
Symptom control: pruritus and fatigue are often the most impactful symptoms for quality of life and should be actively managed alongside disease‑modifying therapy.